Why is Concord Biotech falling/rising?

As of 11-Sep, Concord Biotech Ltd is experiencing a decline in its stock price, currently at 1,636.05, which reflects a decrease of 14.0 points or 0.85%. The stock has underperformed its sector today by 1.32% and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has decreased by 1.83%, while it has shown a modest increase of 2.03% over the past month. However, the year-to-date performance is concerning, with a significant drop of 25.97%. The company has reported a high management efficiency with a return on equity (ROE) of 19.76% and a low debt-to-equity ratio, but these positive factors are overshadowed by poor long-term growth indicators, such as a 52.6% decline in profit after tax compared to the previous quarter's average and the lowest net sales recorded at Rs 203.99 crore.
In the broader market context, the Sensex has increased by 1.03% over the past week and 1.17% over the past month, indicating a stronger performance compared to Concord Biotech. The stock's underperformance is further highlighted by a decline in institutional investor participation, which has decreased by 0.54% in the previous quarter, suggesting a lack of confidence from more knowledgeable market players. Additionally, the stock's valuation appears expensive with a price-to-book value of 9.5, and its PEG ratio of 3.5 indicates that the stock may not be a favorable investment relative to its earnings growth. Overall, the combination of poor financial performance, declining institutional interest, and a lack of momentum in the stock price contributes to its downward trajectory.